Biopharma Business

Tag "suliqua"

EU approval for Sanofi’s type 2 diabetes treatment

The European Commission (EC) has granted marketing authorisation in Europe for Sanofi‘s Suliqua, a titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here